DEFA14A: STAAR Surgical Amends Alcon Merger, Adds Go-Shop Period

STAAR Surgical Company has supplemented its proxy statement, announcing an amendment to its merger agreement with Alcon Research, LLC, introducing a 30-day go-shop period and eliminating termination fees under certain conditions.

Summary

• STAAR Surgical Company (STAAR) has issued a supplement to its proxy statement, detailing an amendment to its merger agreement with Alcon Research, LLC (Alcon).
• The amendment establishes a 30-day "go-shop" period, from November 7, 2025, to December 6, 2025, during which STAAR can actively solicit alternative acquisition proposals.
• During this period, STAAR is not obligated to inform Alcon of proposals, and Alcon forfeits its right to match any superior offers.
• The termination fee payable by STAAR to Alcon has been reduced to $0 if STAAR accepts a Superior Offer from a Qualified Bidder, a significant reduction from the previous potential fee of up to $43,425,000.
• The Special Meeting of Stockholders, where shareholders will vote on the merger, has been postponed for a third time, now scheduled for December 19, 2025.
• Major shareholders, including Broadwood Partners, L.P. (approximately 27.4% ownership) and Yunqi Capital Limited (5.1% ownership), have publicly stated their intent to vote against the merger proposal.
• The STAAR Board of Directors approved the amendment, with one director dissenting, and continues to recommend the merger.

Sentiment

Score: 7

Explanation: The amendment introduces a go-shop period and eliminates termination fees for superior offers, which is favorable for shareholders seeking maximum value. However, the repeated postponements of the Special Meeting and significant shareholder opposition from Broadwood and Yunqi indicate ongoing challenges and uncertainty regarding the merger's approval.

Positives

• Introduction of a 30-day "go-shop" period (November 7, 2025, to December 6, 2025) allows STAAR to proactively seek superior acquisition offers.
• Elimination of Alcon's right to match a third-party Acquisition Proposal facilitates a more open and competitive process.
• Reduction of the termination fee payable by STAAR to Alcon to $0 if STAAR accepts a Superior Offer from a Qualified Bidder, significantly lowering the cost for STAAR to pursue a better deal.
• The Board's determination that the amended merger agreement is advisable, fair, and in the best interests of STAAR and its stockholders.

Negatives

• The Special Meeting has been postponed multiple times, potentially indicating uncertainty or difficulty in securing shareholder approval.
• Significant opposition from major shareholders: Broadwood Partners, L.P. (approx. 27.4% ownership) and Yunqi Capital Limited (5.1% ownership) intend to vote against the Merger Proposal.
• Broadwood Group has initiated a proxy contest, soliciting votes against the Board's recommendations, which could cause additional costs and impair STAAR's ability to obtain required votes.
• One director dissented from the Board's approval of the Amendment, citing shareholder opposition and concern that potential alternative acquirers might be disincentivized.

Risks

• The possibility that no alternative proposals will be received during the go-shop period, or that any such proposals are not determined by the Board to be superior to the Alcon merger.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders, especially given significant opposition from major shareholders.
• Failure to obtain required regulatory approvals or satisfy other closing conditions.
• Risks related to disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.
• The proxy contest initiated by Broadwood Group could cause additional solicitation and other costs and impair STAAR's ability to obtain the votes required.

Future Outlook

The go-shop period is intended to maximize stockholder value by facilitating an increase in the price offered by Alcon or an alternative bidder. The Board continues to recommend the merger with Alcon, as amended, but acknowledges the risk that no alternative proposals will be received or deemed superior. If the merger is not completed, STAAR will remain an independent public company, its stock will continue to trade on NASDAQ, and it will continue to file reports with the SEC.

Management Comments

• "Your Vote Is Important, Please Use the Updated WHITE Proxy Card Today!"
• "We recommend that STAAR stockholders disregard any proxy card sent to them by or on behalf of any person other than STAAR, including any green proxy card and solicitation materials that may be sent to STAAR stockholders by or on behalf of Broadwood Group."

Industry Context

The filing reflects ongoing M&A activity in the medical device and ophthalmology sector, with a larger player (Alcon) seeking to acquire a specialized company (STAAR Surgical). The introduction of a "go-shop" provision and reduced termination fee are mechanisms often employed in M&A to ensure a robust market check and address shareholder concerns about deal value, especially when there is significant shareholder dissent.

Corporate Governance

Legal Proceedings

• Broadwood Partners, L.P. and its affiliates (Broadwood Group) have filed a definitive proxy statement to solicit votes in opposition to the Board's recommendations, indicating an active proxy contest.

Stakeholder Impact

• Shareholders: Potential for increased value if a superior offer emerges during the go-shop period. Risk of stock price decline if the merger fails. Required to vote on the merger and executive compensation.
• Management/Employees: Disruption to attention from ongoing business operations due to the proposed transaction. Potential impact on retention and hiring of key personnel.
• Customers/Suppliers: Potential impact on relationships due to the proposed transaction.

Next Steps

• STAAR will continue to solicit votes for the Merger Proposal and Compensation Proposal using the updated WHITE proxy card.
• The go-shop period will continue until December 6, 2025, during which STAAR will solicit alternative acquisition proposals.
• The Special Meeting of Stockholders will be held virtually on December 19, 2025, to vote on the Merger Proposal and Compensation Proposal.
• If a Superior Offer is received from a Qualified Bidder during the go-shop period, the Board may change its recommendation or terminate the agreement without a termination fee.

Key Dates

Recommendation

The introduction of a go-shop period and the elimination of termination fees for a superior offer create an opportunity for a potentially higher bid, which is positive for shareholders. However, the significant opposition from major shareholders (Broadwood and Yunqi) and the repeated postponements of the Special Meeting introduce considerable uncertainty regarding the current merger's approval. An investor should hold to see if a superior offer materializes during the go-shop period and monitor the outcome of the shareholder vote, as the current $28.00 offer might not be the final or best outcome. The proxy contest also adds a layer of complexity and potential volatility.

Keywords

STAAR Surgical Company, Alcon Research, Merger Agreement, Go-Shop Period, Acquisition Proposal, Termination Fee, Proxy Statement, Special Meeting, Shareholder Vote, Corporate Governance, M&A, Ophthalmology, Medical Devices